Copyright
©The Author(s) 2020.
World J Gastrointest Oncol. Nov 15, 2020; 12(11): 1237-1254
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1237
Published online Nov 15, 2020. doi: 10.4251/wjgo.v12.i11.1237
Figure 6 Overexpression of HOXD-AS2 inhibits the PI3K/Akt signaling pathway.
A, D, and E: Overexpression of HOXD-AS2 reduced p-PI3K, p-Akt, and p-MDM2 protein levels, and increased p53 and HOXD8 protein levels; B: HOXD-AS2 mRNA levels were significantly increased following treatment with LY294002 in SGC-7901 (P = 0.009) and SNU-1 (P = 0.001) cells for 48 h. Expression levels were normalized to GAPDH levels. The results are shown as the mean ± SD; C, F, and G: HOXD8 and p53 protein levels were significantly increased but p-PI3K, p-Akt, and p-MDM2 protein levels were significantly reduced following treatment with LY294002 in SGC-790 and SNU-1 cells for 48 h. aP < 0.05, bP < 0.01, eP < 0.001.
- Citation: Yao L, Ye PC, Tan W, Luo YJ, Xiang WP, Liu ZL, Fu ZM, Lu F, Tang LH, Xiao JW. Decreased expression of the long non-coding RNA HOXD-AS2 promotes gastric cancer progression by targeting HOXD8 and activating PI3K/Akt signaling pathway. World J Gastrointest Oncol 2020; 12(11): 1237-1254
- URL: https://www.wjgnet.com/1948-5204/full/v12/i11/1237.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v12.i11.1237